Combinations of empagliflozin/linagliptin for 24 weeks as add-on to metformin in subjects with Type 2 diabetes

被引：0
|
作者：
Defronzo, R. A. [1 ]
Lewin, A. [2 ]
Patel, S. [3 ]
Liu, D. [4 ]
Kaste, R. [4 ]
Woerle, H. J. [5 ]
Broedl, U. C. [5 ]
机构：
[1] Univ Texas Hlth Sci, San Antonio, TX USA
[2] Natl Res Inst, Los Angeles, CA USA
[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[4] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
DIABETIC MEDICINE | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P196
引用
收藏
页码：90 / 90
页数：1
相关论文
共 50 条
  • [1] Fixed dose combinations of empaglilozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes
    Patel, S.
    DeFronzo, R.
    Lewin, A.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETOLOGIA, 2014, 57 : S7 - S7
  • [2] Combinations of empagliflozin/linagliptin for 24 weeks in drug-naive subjects with Type 2 diabetes
    Lewin, A.
    DeFronzo, R. A.
    Patel, S.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETIC MEDICINE, 2015, 32 : 90 - 90
  • [3] Safety and tolerability of combinations of empagliflozin/linagliptin for 52 weeks in subjects with type 2 diabetes
    Kohler, S.
    Patel, S.
    DeFronzo, R. A.
    Lewin, A.
    Liu, D.
    Kaste, R.
    Woerle, H. -J.
    Broedl, U.
    [J]. DIABETOLOGIA, 2015, 58 : S363 - S363
  • [4] Empagliflozin as add-on to metformin in patients with Type 2 diabetes
    Merker, L.
    Haering, H. U.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [5] Empagliflozin as add-on to metformin in people with Type 2 diabetes
    Merker, L.
    Haering, H-U.
    Christiansen, A. V.
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETIC MEDICINE, 2015, 32 (12) : 1555 - 1567
  • [6] Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES, 2013, 62 : A282 - A282
  • [7] Empagliflozin as add-on to metformin plus sulfonylurea in patients with Type 2 diabetes
    Haering, H. U.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [8] Empagliflozin as add-on to pioglitazone with or without metformin in patients with Type 2 diabetes
    Kovacs, C. S.
    Seshiah, V.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Stella, P.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETIC MEDICINE, 2015, 32 : 88 - 88
  • [9] Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
    Haering, Hans-Ulrich
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 110 (01) : 82 - 90
  • [10] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
12345